Drugs that have been withdrawn from international marketplaces between 1995 and 2005 due to associated hepatotoxicity.
1.1. The cost of new drugs and need to streamline drug development
Innovation is fundamental to discovering new drugs for the variety of human conditions that exist. It is also one of the key requirements for any pharmaceutical organization that wishes to gain a competitive edge. The pharmaceutical industry is profit-driven because it has to fund its own drug innovation, which highlights why research and development (R&D) forms the backbone of this industry. According to the CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), John Castellani, member companies of PhRMA spent a record US$ 67.4 billion on R&D in 2011. This is approximately 20% of generated revenue, which is 5 times more than the average manufacturing firm invests into R&D . The pharmaceutical sector was responsible for 20% of all R&D expenditures by U.S. businesses in 2011 . The aforesaid figures do not describe global R&D expenditures, but serve to give some indication of the astronomical contributions that are annually devoted by the pharmaceutical industry to drug development.
Substantial fiscal investments are made against the backdrop of enormous investment risks. It is estimated that only 5 of every 10 000 compounds explored will make it to clinical trials . Although the likelihood that an investigational new drug in clinical testing reaches the market has increased over the past couple of decades to 16%, the probability is still low. Furthermore, of those that do get approved, only 2 or 3 out of every 10 drugs recover their full pecuniary investment . The stakes are incredible and the strain on the industry as a whole is overt. In 2011 the world's largest research-based pharmaceutical company, Pfizer, closed its R&D centre located in the U.K. owing to financial viability concerns. In an attempt to dissuade some of the financial pressures, many companies have opted for mergers to either maintain existing pipelines or acquire new development opportunities .
A fairly regular citation estimates the out-of-pocket, pre-approval cost per drug developed to be more than US$ 800 million . Estimations reported in peer-reviewed literature ranges from US$ 391 million  to US$ 1.8 billion . Evident from literature is the fact that the estimates increase over time, in other words, the cost of developing drugs is escalating, which implies ever-increasing financial pressures on industry.
Two of the most prominent concerns for the pharmaceutical industry are patent expirations and attrition rates. Patent expirations result in decreased revenue generation and, as stated, this industry is profit-driven, meaning that diminished earnings cripple the R&D of an organization. Not only does this predict deterioration for a pharmaceutical company, but decreased R&D output also slows the production of new drugs. This also has a major impact on healthcare. It is estimated that in the U.S. a new case of Alzheimer's develops every 68 seconds . Using these figures, more than 460 000 new cases of Alzheimer's will develop each year the approval of an effective new drug is delayed. Whereas patent expirations prune generated revenues, attrition rates affect the opposite side of the equation, needlessly raising the cost of developing new drugs. Attrition rates are high (Figure 1). A chemical entity that reaches phase I clinical trials has a 71% chance of reaching phase II clinical trials. Those chemical entities that do reach phase II trials have only a 31% chance of entering phase III trials. Further compounding the issue are rising failure rates in phase III trials . Attrition drives development costs for two reasons: 1) monetary investments into failed ventures are lost and 2) failing development programs occupy resources and time that could otherwise be spent on drug candidates that would eventually succeed to be approved for marketing.
Together, patent expirations and drug attrition add enormous strain on new drug development, in a cumulative way inhibiting productivity and output of the entire R&D process. An article recently published by Forbes offers some perspective on the impact of attrition on development costs . According to this article, AstraZeneca has been plagued by development failures, which escalated their average cost to develop a new drug to US$ 12 billion. In comparison, for Eli Lilly the average cost of developing a new drugs is estimated at only US$ 4.5 billion. The difference in development cost between the two companies can be attributed to the difference in approval rates of new drug i.e. less failures .
The average times, from the start of a particular phase to entering the next phase, are 4.3 years for pre-clinical development and 1.0, 2.2 and 2.8 years for phase I, II and III trials, respectively. Regulatory perusal adds another 1.5 years to the entire process . Collectively, the duration of drug development from initiation of clinical testing until drug approval is estimated at 7.5 years . Including pre-clinical development, it takes, on average, 10 - 15 years to develop a new drug from its discovery to regulatory approval [1,4] (Figure 2). A study that investigated the reduction in costs associated with drug development with improved productivity of the process reported that a 5% reduction in total development time will decrease development costs by 3.5% . Although this may not sound like much, 3.5% of US$ 1 billion is a substantial saving. The study also emphasized the reduction in costs if decisions to terminate unproductive development programs are shifted to earlier phases of the discovery process. For example, the study estimated that if a company manages to shift a quarter of its decisions to terminate from phase II to phase I, it would save US$ 22 million . Again, it relates back to why attrition drives development costs. Making the decision to terminate (a development program) earlier would stop further investment into unfruitful programs and free resources to promote approval ratings.
Industry continuously struggles to bring new drugs to the market, despite the process being overextended, costly and particularly uncertain of success. Over the last decade, overall drug development time has increased by 20% and the rate of approval of new chemical entities has dropped by 30% . There is a mounting need to nurture output from the drug development process. Minor restructuring and streamlining of this process is required to increase its productivity and alleviate some of the financial pressures that drug developers experience. One area in particular where pruning of this process is overdue is the early pre-clinical detection / prediction of potential hepatotoxic chemical entities.
2. Attrition due to hepatotoxicity
Drug-induced liver injury (DILI) is a challenge for both the pharmaceutical industry and regulatory authorities. The most severe adverse effect that DILI may lead to is acute liver failure, resulting in either death or liver transplant. Of all the cases of acute liver failure in the U.S., between 13% and 50% can be attributed to DILI [11,12]. Without a doubt there is great concern for the safety of consumers exposed to drugs that may cause DILI because patients have only one liver. For this reason, government and the public put pressure on regulatory authorities to establish safer drugs . However, if regulatory authorities unnecessarily raise safety standards without scientific evidence, this will discourage drug development because of attrition, which is predominantly unwanted when considering the current scenario where fewer antimicrobials are being developed alongside increased antibiotic resistance.
A prevailing issue in drug development is the attrition of new drug candidates. Between 1995 and 2005, a total of 34 drugs were withdrawn from various markets (Table 1) and the reason for withdrawal in the majority of cases was hepatotoxicity . Hepatotoxicity is the leading cause of drug withdrawals from the marketplace [15-17]. Examples include the monoamine oxidase inhibitor, iproniazid, the anti-diabetic drug, troglitazone, and the anti-inflammatory analgesic, bromfenac, all of which induced idiosyncratic liver injury. Iproniazid, the first monoamine oxidase inhibitor released in the 1950's, was probably the most hepatotoxic drug ever marketed . Troglitazone was available on the U.S. market from March 1997. By February 2000, 83 patients had developed liver failure, of which 70% died. Of the 26 survivors, 6 required liver transplants . While on the market, troglitazone accrued approximately US$ 700 million per year . Withdrawals of lucrative drugs like troglitazone diminish return on investments and threaten further R&D.
Of all classes of drugs, non-steroidal anti-inflammatory drugs (NSAIDs) have had one of the worst track records regarding hepatotoxicity. Benoxaprofen and bromfenac are two NSAIDs that were withdrawn from public use after reports of hepatotoxicity [16,19]. Benoxaprofen was withdrawn in 1982, the same year that it was approved . Bromfenac was predicted to earn around US$ 500 million per year .
Although diclofenac is widely used to treat rheumatoid disorders, approximately 250 cases of diclofenac-induced hepatotoxicity have been reported. In perspective, DILI caused by diclofenac has an incidence of 1-2 per every million prescriptions [20,21], being high enough that a considerable amount of literature has been generated warning against diclofenac-induced hepatotoxicity. Between 1982 and 2001 in France, more than 27 000 cases of NSAID-induced liver injuries were reported. Clometacin, and silundac were the NSAIDs with the highest risk of DILI. Over the same peroid approximately 2100 cases of NSAID-induced liver injuries were reported in Spain, with the main culprits being droxicam, silundac and nimesulide . Acetaminophen (a.k.a. paracetamol) must be the most notorious of all the NSAIDs, if not all drugs, when it comes to DILI. Its mechanism of hepatotoxicity is better understood than its therapeutic mechanism of action. Fortunately, acetaminophen has a substantial therapeutic index and copious amounts need to be administered before the liver will not be able to manage its onslaught anymore .
Troglitazone was available on the U.S. market for three years before withdrawal, during which time it was used by almost 2 million patients, realising some return on investment . Ximelagatran, on the other hand, was in the very late stages of development when its fate was sealed. In fact, AstraZeneca had already applied at the EMEA for marketing approval when the company withdrew all applications due to concerns over the hepatotoxic potential of the drug . Although this drug did reach the market in France, the U.S. FDA was not prepared to grant approval and the drug was never marketed in the U.S. . Ximelagatran, which was the first orally available thrombin inhibitor that would have replaced the troublesome warfarin as an oral anticoagulant, serves as a good example where huge investments were made to get the drug to market, but a return on investment was never realised. This example emphasizes the necessity for improved methodologies to predict intrinsic hepatotoxicity more accurately during the initial phases of the drug development process.
Examples of other drugs that were never marketed in the U.S. because of hepatotoxicity include drugs such as ibufenac, perhexilene and dilevalol. There are also drugs for which the use / application has been limited because of possible DILI. These include the drugs isoniazid, pemoline, tolcapone and trovafloxacin . A big question that remains a challenge for regulatory authorities is how rare or mild does hepatotoxicity have to be for a drug to be approved and to remain on the market?  Undoubtedly, DILI has a sizeable influence on drug development output. Pre- and post-marketing attrition as a result of DILI causes further financial stresses for those in the industry. Limiting attrition to the early phases of drug development can only be beneficial. Both the pharmaceutical industry and regulatory authorities agree that there is a great need for improved methodologies and strategies to accurately assess the hepatotoxic potential of compounds, earlier in the drug development process [13,26].
3. Safety pharmacology and current practices used to detect hepatotoxicity
Distinct from pharmacology proper, which examines the desired effects and kinetics of a particular drug, safety pharmacology identifies and characterises secondary adverse pharmacological and toxicological effects of potential drugs, mainly through the use of established animal models . Regulatory authorities require that certain minimal safety pharmacology examinations be completed before a new investigation drug application will be approved. These international regulatory guidelines were compiled by the International Committee for Harmonization (ICH) in the documentation covering topic S7. The ICH S7A and ICH S7B guidelines have been in effect since 2000 and 2001, respectively .
At present, the attention of pre-clinical safety pharmacology investigations is drawn to three physiological systems: the cardiovascular system, the respiratory system and the central nervous system (for compounds that may cross the blood-brain barrier). Effects on the cardiovascular system are of great concern because 1) it is a system often found to be affected and 2) due to its redundancy (organisms relevant to drug development have only one heart). Like the heart, the respiratory system is of concern because it is essential to the immediate survival of the organism.
Hepatic safety does not form part of the core battery of pre-clinical tests performed for initial safety pharmacology. The EMEA have published draft guidance on the non-clinical assessment of hepatotoxic potential . This draft amounted to a clinical white paper , however, no regulations are set in place yet. This initial draft may demonstrate the future intent of regulatory authorities. If this is the case, not only is it worthwhile for the pharmaceutical companies to consider improved pre-clinical evaluation of hepatotoxic potential for their own profit, but it may soon be required as part of their investigational drug applications before first-in-human trials.
Elevations of > 3 × ULN are considered a sensitive signal of a potential hepatotoxic test compound. Data from 28 clinical trials (phases II - IV) conducted by GlaxoSmithKline between 1995 and 2005 found elevations in ALT of > 3 × ULN at baseline to be rare, with a prevalence of 6.265% . A study of Merck clinical trial databases, reported that elevations of ALT or AST > 3 × ULN had an 83% sensitivity to detect serious liver disease [Senior, 2003]. ALT > 3 × ULN has proved a useful threshold for screening for clinically significant DILI from various hepatotoxic substances. This includes drugs that have been withdrawn from the market due to hepatotoxicity, such as troglitazone and bromfenac . However, this is not a very specific signal as increases in aminotransferase levels can also be induced by drugs that do not cause DILI such as aspirin, statins and heparin . Indeed, the Merck study showed that the predictive power of elevations of ALT or AST > 3 × ULN, was only 11% . A separate manuscript also reported high sensitivity and specificity when using ALT > 3 × ULN, but again with very low predictive power (only 6%) . Serum ALT or AST levels are therefore a sensitive screen for possible hepatotoxic side-effects, but not definitive enough to terminate a drug development program.
Even though it was originally not intended as such, the most successful predictor of hepatotoxicity is “Hy’s law”, which is based on the original observations made by Dr. Hyman Zimmerman. It was described by Dr. Zimmerman as "clinical jaundice" and its modern application has proved valuable in being able to predict idiosyncratic hepatotoxicities brought about by drugs / potential drugs such as troglitazone and dilevalol. A more recent description is a state of drug-induced jaundice caused by hepatocellular injury, without any significant obstructive component [17,35]. Therefore, Hy’s Law is met when:
There exists the possibility that a drug (or potential drug) can induce hepatocellular damage as evident from elevations in serum aminotransferase levels of ≥ 3 × ULN and
These elevations are accompanied by elevations in total bilirubin of ≥ 2 × ULN with no evidence of intra- or extra-hepatic obstruction (elevated ALP) or Gilbert’s syndrome.
It is worth noting that Dr. Zimmerman himself placed some weight on the degree of jaundice as it often served to predict a negative outcome . Hy's Law is, however, not exclusive to DILI and if it is met, it is of utmost importance that any other condition(s) that may also cause these symptoms be excluded before any conclusions are drawn about a potential intrinsic hepatotoxin. Such conditions may include viral hepatitis, hypotension or congestive heart failure . Obviously, the possibility of DILI caused by concomitant drugs should also be excluded.
The incidence of idiosyncratic DILI is generally 1 per 10 000 or less. This makes it exceptionally difficult to detect idiosyncratic hepatotoxicity due to an investigational drug during clinical testing, even if several thousands of subjects are studied . Generally, an investigational drug does not get administered to more than 2000 subjects , which makes it unlikely to detect a single incidence in 10 000. Although it portrays the role of the key predictor of the hepatotoxic potential of an investigational drug during drug development, Hy's Law falls short of constituting a "gold standard'" and validation of Hy's Law is much needed, chiefly with regards to its sensitivity and specificity . Moreover, for the purposes of detecting potential intrinsic hepatotoxins as early as possible during drug development, the foremost drawback of Hy’s law is that it requires
4. Methodologies applicable to the early pre-clinical assessment of potential intrinsic hepatotoxicity
The ultimate goal of research into this field is to establish an
4.1. Cell-based models
4.1.1. Cell cultures
Cell-based models are increasingly used as there is a growing pressure to reduce, refine and replace the use of animals from organisations such as the European Centre for the Validation of Alternative Methods (ECVAM). The three basic types of cells used for
The use of immortalized human hepatocytes cell lines, like HepG2 cells, were proposed to overcome limitations of primary human hepatocytes including the scarce availability of fresh human liver samples, complicated isolation procedures, short life-span, inter-donor variability, and cost. HepG2 cells display morphological features similar to that of liver parenchymal cells and maintain many functions of
The chief advantage that primary cell cultures have over most perpetual cell lines is that they are the closest
Two techniques have received attention over the years to try and improve the life-span of primary hepatocytes in culture. These are sandwich culturing techniques and special medium formulations. Sandwich culturing techniques address the conformational / spatial discrepancies between the 2D
The problems of low levels of enzyme expression in HepG2 cells and limited life-span of primary hepatocytes was overcome with the emergence of the HepaRG cell line. These cells express higher levels of CYP's than HepG2 cells and respond acutely to induction of these enzymes . HepaRG cells maintain hepatic functions of primary hepatocytes and express normal levels of liver-specific genes while lacking the inter-donor variability observed with primary hepatocytes [50,54]. A lot of literature praises HepaRG for the increased metabolic activity, which allows the
4.1.2. Outcomes and detection methods
Researchers at Pfizer postulate that the poor predictive power of conventional cytotoxicity assays is related to the endpoint being measured . Cytotoxicity endpoint assays only assess the final extreme from a series of pathological events that lead to cellular death. Assays that target such late events are likely to fail in detecting more subtle types of toxicity that develop after chronic, low-dose exposure to manifest as non-lethal, but definite adverse, complications . In addition to this, the liver is the only organ in mammals that can fully regenerate after injury , making testing for adaptive changes even more relevant and applicable. An example of this scenario of subtle toxicity can be found in troglitazone, which exerts sub-acute hepatotoxicity by acting on a sub-cellular level, disrupting mitochondrial homeostasis. The mechanism of toxicity of troglitazone was investigated by means of
An important tool that was used in the MEIC study, and remains relevant to current methodologies, is that of mathematical modelling. In the MEIC study, researchers employed partial least squares regression . Mathematical modelling provides a way in which researchers can combine data from different endpoint assays, thereby allowing them to piece together underlying associations and correlations observed when drugs (or groups of drugs) affect normal cellular function. Previous research illustrated how mathematical modelling of multiparametric data can aid prediction . Seventeen compounds (7 known hepatotoxins and 10 "unknowns") were subjected to testing using 6 separate endpoint assays monitored with a fluorescent plate reader. The data was then used to develop 5 prediction models. Modelling techniques included logistic regression, support vector machines (using several different kernel functions), decision tree, quadratic discriminant analysis and neural networks. Discriminant analysis was found to yield the best positive and negative predictive values . In addition, the study highlighted the significance of adequate sample size and careful consideration and defining of positive and negative test values in the training data set. It is important to realise that the task of predicting DILI from
As with the study by Flynn and Ferguson , high content screening (HCS), which is based on automated microscopy, also employs fluorescent probes. HCS is one cell-based methodology that has shown promising results in predicting DILI. This methodology has three key strengths: 1) the ability to simultaneously examine multiple parameters of cellular function, 2) all parameters can be examined in individual cells, and 3) it has the potential for high-throughput screening since it is based on a microplate format. Combined, these features culminate in powerful technology. Testing more than 240 drugs using an HCS platform, researchers at Pfizer demonstrated that this methodology had overall sensitivity and specificity of 90% and 98%, respectively, for predicting
Another fluorescence detection method that has a potential role in early pre-clinical assessment of intrinsic hepatotoxicity is flow cytometry. Essentially, this method of detection can analyse the same parameters as fluorometry and fluorescence microscopy. It has not been explored in as much detail as HCS, but initial reports are positive . There is room for research comparing these different methods of detection and the verdict is still out on which platform outperforms the rest.
4.2. Profiling technologies
Virtually all responses to toxic insults are accompanied by differential gene expression . Differential gene expression is likely to be accompanied by differential transcription and differential protein expression (adaptive responses in Figure 3). On this conceptual basis, researchers have tried to use profiling technologies such as genomics / transcriptomics and proteomics to discern between compounds that may or may not induce liver injury and even between subsets of chemical entities that cause different types of hepatotoxicity like necrosis, steatosis and cholestasis .
The sensitivity of genomics experiments is high enough to detect subtle changes in gene expression profiles. For this reason, it is argued to be more sensitive than conventional methodologies aimed at detecting toxicity . Indeed this was demonstrated in rats exposed to sub-toxic doses of acetaminophen, where subtle changes in gene expression profile were observed although no histological changes manifested . This boasts well for toxicogenomics as being able to identify the most sensitive signals of potential hepatotoxicity. The authors did however emphasise the weight of demarcating toxic events, sub-toxic / adverse events, and adaptive responses as this will have great influence on the outcomes of toxicogenomic studies. The ability to detect responses at a molecular level that are not necessarily revealed at phenotypic level makes it possible to address questions about linearity of the dose-response curve at low exposure levels and allows for more accurate determination of inflection points along to dose-response curve and threshold exposure levels . These determinants can play pivotal roles in safety pharmacology when selecting dosages for clinical studies. Regarding the predictive power of genomics, Zhang
Unlike the genome, the proteome is a dynamic entity that changes as gene activation and epigenetic factors alter protein expression due to endogenous and exogenous signals and factors. Studying the proteome allows the surveillance of current cellular events, which can only be deduced from genomics data. This is probably the greatest disadvantage of toxicogenomics compared to toxicoproteomics; there are many splice variants, post-translational modifications and subcellular localizations of the final products originating from genes [72,73] implying that some degree of extrapolation is necessary when predicting cellular events from genomics data. When studying the proteome, differential expression such as this can be detected and this may in fact form part of the solution, rather than part of the problem.
Studying the proteome provides a direct description of cellular functions . Thus far, toxicoproteomic attempts to predict DILI have demonstrated limited efficacy when performed
Perhaps a more integrated approach would eventually prove more fruitful. Researchers conducted a study in which they characterised methapyrilene-induced hepatotoxicity in rats employing three profiling technologies simultaneously: genomics, proteomics and metabolomics . The report demonstrated the possibility and great value of these technologies when used in an integrative manner, where responses to the toxic insult could be followed from genetic expression changes, to protein up- / down-regulation, through to changes in the metabolite profile, which gave a very good indication of where and how the chemical entity may exert its biochemical action(s). Conducting this type of study on a substantial number of compounds, both hepatotoxic and not, will yield a vast amount of data on how hepatocytes react toward challenges with different types of chemical entities and provide insight into which responses should raise concern and which are harmless. It may also deliver further understanding of the mechanisms by which hepatocyte injury occurs.
One major drawback of all the profiling technologies is that most of the current research has been carried out
4.3. Emerging technologies
The main reason for a lack of
4.3.1. Stem cell technologies
As all physiological processes take place in a cellular setting, the highest quality of cells should be used to determine safety and efficacy. This led to the use of stem cells. Stem cells are classified as embryonic or adult, which is distinguished by developmental status. Where adult stem cells are multipotent (yield the cell type from the tissue from which they originate), embryonic stem cells are pluripotent (can give rise to differentiated cell lineages of all three germ layers). Stem cells that originate from embryos have a normal diploid karyotype and do not exhibit donor-dependent variability. The advantage of these cells compared to primary cells are that they can be maintained in culture for a longer period of time and can be grown up in large scale, producing high volumes.
The implementation of murine embryonic cells to predictably identify human developmental toxins, allowing for early identification of toxicity or candidate compounds in the discovery pipeline was initiated by ECVAM. Mouse hepatocyte-like cells, which were established from embryonic stem cells were the first to be used in hepatotoxicity models. The efficacy of cell differentiation and maturation was improved, where the cells generated alpha fetoprotein and albumin . Cell characteristics included: 70% expressed the phenotypical marker albumin, they metabolized ammonia, lidocaine and diazepamat nearly two-thirds the rate of primary mouse hepatocytes. However, the difference in metabolism between humans and mice is considerable leading to interspecies extrapolation problems. Subsequently hepatocyte-like cells were differentiated from hESC . These cells contained liver-related characteristics such as; expression of α-fetoprotein, production of albumin, hepatocyte nuclear factor 4α and induction of CYP450 enzymes, stored glycogen and showed uptake of idocyanine green. This was followed by more differentiated hepatocyte-like cells which additionally express functional glutathione transferase activity at levels comparable to human hepatocytes .
The advantages of stem cells in relation to transformed/tumour or primary cells are that the former possesses normal growth, genetic transformation and genetic composition as well as uniform physiology and pharmacology . Since stem/progenitor cells can differentiate into clinically relevant cell types, but still maintain functional similarities to their
As with all technologies, there are still hurdles to overcome with stem cell technology. Many clinically relevant cell types cannot be efficiently differentiated, purified and isolated . Human stem cells that reproducibly deliver hepatocytes with predictive pharmacology results for high-throughput safety screens are limited. Although progress has been made in the differentiation protocols, scaling cell growth and plating for cell-based assays, as well as refining of these protocols in order to ensure homogeneous preparations will continue. Currently, panels of human embryonic stem cells which reflect the wide variation in the population are not available.
Although these hurdles exist, stem cells hold the potential for investigation into metabolic competence, biotransformation capacity and transformation of exogenous compounds. Also, the ability to determine human inter-individual differences due to genetic polymorphisms.
4.3.2. 3D culturing techniques
Although 2D techniques have the advantages of being relatively inexpensive, reproducible, robust and convenient, they have the chief disadvantage of loss of much of the functionality of native hepatocytes , which raises the question of the relevance of such a model in predicting DILI. Three-dimensional culturing of hepatocytes is an attempt to imitate an
The sandwich configuration of 3D culturing is frequently used when propagating primary hepatocytes as it has been shown that maintaining these cells in this configuration prolongs their
A manuscript that unmistakeably illustrates the important role that 3D culturing techniques can play in drug development is Lee
It is difficult for nutrients to reach, and for waste products to be removed from hepatocytes in a traditional sandwich configuration because the cells are entrapped in a thick extracellular matrix. The perfusion sandwich culture  and entrapment between ultra-thin porous silicon membranes technologies  were developed to surmount these complications. In addition to maintaining hepatobiliary function, both these methods claim added predictive capabilities for DILI as demonstrated through increased sensitivity to acetaminophen toxicity due to preserved metabolic enzyme functionality. Still, even with these improved methods, the life-span of these primary hepatocytes remains limited, which restricts the use of such methods on a large scale.
Other 3D culturing methods are mainly based on bio-artificial liver bioreactors that are aimed at developing extracorporeal liver support systems for patients with acute liver failure. In the past, such bioreactors were based on adult hepatocytes and proved unsuccessful because the hepatocytes failed to proliferate . The latest of these that are being explored for its use in drug toxicity testing is the four-compartment perfusion model. Cells are contained in one of the four compartments, the remaining three compartments comprises three independent but interwoven artificial capillary bundles that form the capillary bed in which the cells are housed. Cells are derived from hESCs and currently research is being carried out to obtain the optimal protocol for differentiating these cells into mature hepatocytes that closely resemble innate hepatocytes. This research project is headed by the EU Vitrocellomics project .
Anchorage-free 3D culturing methods result in the formation of small hepatocyte aggregates known as spheroids. There are different ways to induce the formation of spheroids including continuously-stirred bioreactors , the rocked suspension technique  and rotating wall bioreactors . Initial experimentation demonstrated that, between spheroids and monolayers, there was indeed differential toxicity induced by 7 day methotrexate exposure. It was thought that this was due to preservation of hepatocyte functionality, but could also have been due to lack of the test compound to penetrate the spheroidal structure . More than a decade later it is well known that liver-specific functions like albumin and urea synthesis and metabolic activities are maintained for prolonged periods of up to 21 days . In time, spheroids deposit an extracellular matrix consisting of laminin, fribronectin and collagen, which encapsulates each individual spheroid. These structures also preserve histotypical cytarchitechture, intercellular contacts (gap junctions) and biliary canaliculi . Moreover, when hepatocytes grown under these conditions are encapsulated in alginate polymers, albumin and urea synthesis doubles and phase I and II metabolic activities are also elevated. This may be attributed to the bulk added to the extracellular matrix, provided by the alginate polymers, which protects the hepatocytes from shear stresses under hydrodynamical conditions . A setback of this technique is the difficulty of obtaining spheroids that are of a specific mean diameter (100 μm) and batches of spheroids that are all similar in size. This is necessary as necrotic cell death may occur at the centre of spheroids if the diameter of these aggregates exceeds approximately 300 μm. The reason for this is lack of oxygen perfusion to cells located in the central region of spheroids that are too large in size .
Recently researchers attempted to predict hepatotoxicity employing hepatocyte spheroids developed from an immortalised cell line, a HepG2 derivative (C3A), instead of primary hepatocytes . The study emphasizes the value of proper dosing during toxicity testing. In the study spheroids were not exposed to a set concentration of drug in the culture medium for individual experiments. Rather, the concentration of drug in the culture medium was adjusted with each experiment to mimic
5. Future directions
It would be fair to say that 2D culturing techniques have predominated since the inception of research on artificially cultured cells and as such numerous ways have been developed to analyse cells in the 2D format. Amongst others, this is one of the key advantages that 2D culturing techniques have over 3D culturing techniques, demonstrated by the multiple parameters that can be simultaneously assessed using HCS. Currently, this is not possible when using 3D cultures as all cells are not in the same pane and cannot be examined individually. On the other hand, the relevance of 2D culture models is questionable when compared to 3D models that more closely resemble their native counterparts. Various reports have shown that 3D culturing methods are superior to 2D cultures in detecting or predicting certain types of DILI, especially cholestatic injury as 2D models do not express the necessary morphology to study this. Profiling technologies may be able to breach the chasm between 2D and 3D culture models because it is applicable to both scenarios and have been shown to distinguish cholestatic hepatotoxins even when applied to 2D cultures.
The proteome represents current events on a cellular level and 3D cultures are better depictions of innate hepatocytes. Therefore, proteomic investigations that are based on 3D cultures, dosed using
What is missing from current literature is the assessment of 3D cultures to express / secrete biomarkers that are currently used in the clinical setting, i.e. ALT, AST, ALP and bilirubin, and how these respond following challenge with various drugs. Research into this area may uncover possible accurate extrapolations that can be validated for use in predicting DILI. For instance, it is possible that 3D cultures secrete sufficient quantities of ALT and bilirubin to be measured in the surrounding culture medium. Maybe these markers will fluctuate in a way similar to what would occur in the
Work is necessary to incorporate the available methods into a standard set of tests, comprising of different tiers, which generate data that can be interpreted as a whole, to aid the critical ‘go’ / ‘no-go’ decision (the earlier, the better). Such a set of experiments will greatly improve lead prioritization before astronomical amounts of funds are invested into a particular potential drug. In the long run this will increase the productivity of the entire drug development process by alleviating some of the financial pressures and improving time-scales from drug discovery to marketing as less time is spent on candidates that will eventually fail in the clinical phases. Finally, it should aid regulatory authorities in granting approval and provide safer drugs for consumers.
European Centre for the Validation of Alternative Methods (ECVAM); Drug metabolism and pharmacokinetic (DMPK); Drug-induced liver injury (DILI); High content screening (HCS); International Committee for Harmonization (ICH); Multicentre evaluation of
Castellani JJ. Problems and possibilities in the pharmaceutical industry. Vital Speeches of the Day 2011 September; 77(9): 324-327.
Castellani JJ. Pharmaceutical industry critics: How dare they? Vital Speeches of the Day 2012 June; 78(6): 175-178.
Curtis MJ, Pugsley MK. Attrition in the drug discovery process: lessoms to be learned from the safety pharmacology paradigm. Expert Review of Clinical Pharmacology 2012; 5(3): 237-240. DOI: 10.1586/ecp.12.22
DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. Journal of Health Economics 2003; 22: 151-185.
DiMasi JA. Cost of innovation in the pharmaceutical industry. Journal of Health Economics 1991; 10: 107-142.
Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nature Reviews Drug Discovery 2010; 9: 203-214.
LaFerla FM. Preclinical success against Alzheimer's disease with an old drug. The New England Journal of Medicine 2012; 367: 570-572.
Herper M. Strategies: The truly staggering cost of inventing new drugs. 2012 http://www.forbes.com/forbes/2012/0312/strategies-pharmaceuticals-lilly-stagger-cost-inventing-new-drugs.html (accessed 15 August 2012).
DiMasi JA. The value of improving the productivity of the drug development process: Faster times and Better decisions. Pharmacoeconomics 2002; 20(Suppl 3): 1-10.
Valentin J-P, Hammond T. Safety and secondary pharmacology: Successes, threats, challenges and opportunities. Journal of Pharmacological and Toxicological Methods 2008; 58: 77-87. DOI: 10.1016/j.vascn.2008.05.007
Park BK, Kitteringham NR, Powell H, Pirmohamed M. Advances in molecular toxicology - towards understanding idiosyncratic drug toxicity. Toxicology 2000; 153: 39-60.
Ostapowicz G, Fontana RJ, SchiødFV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centres in the United States. Annals of Internal Medicine 2002; 137: 947-954.
Spilker B. Impact of hepatotoxicity on the pharmaceutical industry. FDA-PhRMA-AALSD Conference, Virginia, February 2001. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ucm091365.htm (accessed on 22 August 2012).
Need AC, Motulsky AG, Goldstein DB. Priorities and standards in pharmacogenetic research. Nature Genetics 2005; 37(7): 671-681.
CDER-PhRMA-AASLD Conference 2000. Clinical White Paper. November 2000. http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/ucm091457.pdf (accessed 17 August 2012).
Temple R. Drug induced liver injury: A national and global problem. FDA-PhRMA-AALSD Conference, Virginia, February 2001. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ucm091365.htm (accessed on 22 August 2012).
Temple R. Hy’s law: predicting serious hepatotoxicity. Pharmacoepidemiology and Drug Safety 2006; 15: 241-243.
Faich GA, Moseley RH. Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiology and Drug Safety 2001; 10: 537-547. DOI: 10.1002/pds.652
Moses PL, Schroeder B, Alkhatib O, Ferrentino N, Suppan T, Lidofsky SD. Severe hepatotoxicity associated with bromfenac sodium. The American Journal of Gastroenterology 1999; 94(5): 1393-1396.
Purcell P, Henry D, Melville G. Diclofenac hepatitis. Gut 1991; 32(11): 1381-1385.
Bulsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicology and Applied Pharmacology 2003; 192(3): 307-322. DOI: 10.1016/S0041-008X(03)00368-5
Lapeyre-Mestre M, Rueda de Castro AM, Bareille M-P, Garcia Del Poza J,Alvarez Requejo A, Arias LM, et al. Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: Analysis from national spontaneous reporting systems. Fundamemtal and Clinical Pharmacology 2006; 20(4): 391-395.
Muñiz AE, Rose SR, Liner SR, Foster RL. Unsuspected acetaminophen toxicity in a 58-day-old infant. Pediatric Emergency Care 2004; 20(12): 824-828.
European Medicines Agency. Press release: AstraZeneca withdraws its application for Ximelagatran 36-mg film-coated tablets. 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/02/WC500074073.pdf (accessed on 21 August 2012).
Vaughan C. Ximelagatran (Exanta): an alternative to warfarin? BUMC Proceedings 2005; 18: 76-80.
Hughes B. Industry concern over EU hepatotoxicity guidance. Nature Reviews Drug Discovery 2008; 7: 719. DOI: 10.1038/nrd2677
Kinter LB, Valentin J-P. Safety pharmacology and risk assessment. Fundamental and Clinical Pharmacology 2002; 16: 175-182.
European Medicines Agency. Non-clinical guideline on drug-induced hepatotoxicity. 2008 http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003355.pdf (accessed 16 August 2012).
European Medicine Agency. Reflection paper on the non-clinical ecvaluation of drug-induced liver injury (DILI). 2010 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/07/WC500094591.pdf (accessed on 20 August 2012).
Spanhaak S, Cook D, Barnes J, Reynolds J. Species concordance for liver injury: From the Safety Intelligence Program Board. 2008. http://www.biowisdom.com/downloads/SIP_Board_Species_Concordance.pdf (accessed 21 August 2012).
KaplowitzN. Drug-induced liver injury. Clinical Infectious Diseases 2004; 38(Suppl 2): S44-S48.
Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002; 123: 1367-1384.
Hunt CM, Papay JI, Edwards RI, Theodore D, Alpers DH, Dollery C, et al.Monitoring liver safety in drug development: The GSK experience. Regulatory Toxicology and Pharmacology 2007; 49: 90-100.
Björsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42(2): 481-489.
Lewis JH. 'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidemiology and Drug Safety 2006; 15(4): 221-229.
Weil JG, Bains C, Linke A, Clark DW, Stirnadel HA, Hunt CM. Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease. Regulatory Toxicology and Pharmacology 2008; 52: 85-88. DOI: 10.1016/j.yrtph.2008.06.001
Senior JR. Serum transaminase elevations alone lack specificity for detecting rare serious liver disease. Hepatology 2003; 38(Suppl 1): 701A.
Senior JR. Monitoring for hepatotoxicity: What is the predictive value of liver “function” tests? Clinical Pharmacology and Therapeutics 2009; 85(3): 331-334. DOI: 10.1038/clpt.2008.262
U.S. Food and Drug Administration. Guidance for industry. Drug-induced liver injury: Premarketing clinical evaluation. July 2009. http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf (accessed 16 August 2012).
Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Reviews drug Discovery 2004; 3: 711-716.
Bondesson I, Ekwall B, Hellberg S, Romert L, Stenberg K, Walum E. MEIC - A new international multicenter project to evaluate the relevance to human toxicity of in vitro cytotoxicity tests. Cell Biology and Toxicology 1989; 5: 331-347.
Ekwall B, Barile FA, Castano A, Clemedson C, Clothier RH, Dierickx P, et al. MEIC evaluation of acute systemic toxicity: Part IV. The prediction of human toxicity by rodent LD50 values and results from 61 in vitro methods. Alternatives to Laboratory Animals 1998; 26(Suppl 2): 617-658.
Iwasa F, Galbraith RA, Sassa S. Effects of dimethyl sulphoxide on the synthesis of plasma proteins in the human hepatoma HepG2. Biochemical Journal 1988; 253: 927-930.
Gebhardt R. Inhibition of cholesterol biosynthesis in HepG2 cells by artichoke extracts is reinforced by glucosidase pretreatment. Phytotherapy Research 2002; 16(4): 368-372.
Tirmenstein MA, Hu CX, Gales TL, Maleeff BE, Narayanan PK, Kurali E, et al. Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicological Sciences 2002; 69(1): 131-138. DOI: 10.1093/toxsci/69.1.131
O’Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Kresja CM, Slaughter MR, et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Archives of Toxicology 2006; 80: 580-604. DOI: 10.1007/s00204-006-0091-3
Yamashita R, Saito T, Satoh S, Aoki K, Kaburagi Y, Sekihara H. Effects of dehydroepiandrosterone on gluconeogenic enzymes and glucose uptake in human hepatoma cell line, HepG2. Endocrine Journal 2005; 52(6): 727-733.
Anene-Nzelu C, Wang Y, Yu H, Liang LH. Liver tissue model for drug toxicity screening. Journal of Mechanics in Medicine and Biology 2011; 11(2): 369-390.
Westerink WMA, Schoonen WGEJ. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicology In Vitro 2007; 21: 1581-1591.
Gerets HHJ, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalliun S, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biology and Toxicology 2012; 28: 69-87.
Hewitt NJ, Gómez-Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, et al. Primary hepatocytes: Current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metabolism Reviews 2007; 39: 159-234.
Giullouzu A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guilouzu C. The human hepatoma HepaRG cells: A highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chemico-Biological Interactions 2007; 168: 66-73. DOI: 10.1016/j.cbi.2006.12.003
Richert L, Binda D, Hamilton G, Viollon-Abadie C, Alexandre E, Bigot-Lasserre D, et al. Evaluation of the effect of culture configuration on morphology, survival time, antioxidant status and metabolic capacities of cultured rat hepatocytes. Toxicology in Vitro 2002; 16(1): 89-99.
Anthérieu S, Chesné C, Li R, Camus S, Lahoz A, Picazo L, et al. Stable expression, activity and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metabolism and Disposition 2010; 38: 516-525.
Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proceedings of the National Academy of Sciences 2002; 26: 15655-15660.
Hart SN, Li Y, Nakamoto K, Subileau E, Steen D, Zhong X. A comparison of whole genome gene expression profiles of HepaRG and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metabolism and Disposition 2010; 38: 988-994.
Xu JJ, Diaz D, O'Brien P. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chemico-Biological Interactions 2004; 150: 115-128.
Beyer TA, Xu W, Teupser D, auf dem Keller U, Bugnon P, Hildt E, et al. Impaired liver regeneration in Nrf2 knockout mice: role of ROS-mediated insulin/IGF-1 resistance. EMBO Journal 2008; 27: 212-223.
Bova MP, Tam D, McMahon G, Mattson MN. Troglitazone produces a rapid drop of mitochondrial membrane potential in liver HepG2 cells. Toxicology Letters 2005; 155(1): 41-50. DOI: 10.1016/j.toxlet.2004.08.009
Masubuchi Y, Kano S, Horie T. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology 2006; 222(3): 233-239. DOI: 10.1016/j.tox.2006.02.017
Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: Mechanisms and detection during preclinical safety studies. Fundamental and Clinical Pharmacology 2008; 22: 335-353.
Tolosa L, Pinto S, Monato MT, Lahoz A, Castell JV, O’Connor JE, et al. Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. Toxicological Sciences 2012; 127(1): 187-198.
Ansede JH, Smith WR, Perry CH, St. Claire III RL, Brouwer KR. An in vitro assay to assess transporter-based cholestatic hepatotoxicity using sandwich-cultured rat hepatocytes. Drug Metabolism and Disposition 2010; 38: 276-280.
Flynn TJ, Ferguson MS. Multiendpoint mechanistic profiling of hepatotoxicants in HepG2/C3A human hepatoma cells and novel statistical approaches for development of a prediction model for acute hepatotoxicity. Toxicology in Vitro 2008; 22(6): 1618-1631.
Zanese M, Suter L, Roth A, De GiorgiF, Ichas F. High-throughput flow cytometry for predicting drug-induced hepatotoxicity. In: Clinical Flow Cytometry - Emerging Applications. InTech 2012 ISBN 978-953-51-0575-6.
Nuwaysir EF, Bittner M, Trent J, Barrett JC, Afshari CA. Microarrays and toxicology: The advent of toxicogenomics. Molecular Carcinogenesis 1999; 24: 153-159.
Van Summeren A, Renes J, Bouwman FG, Noben J-P, van Delft JHM, Kleinjans JCS, et al. Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicological Sciences 2011; 120(1): 109-122.
Daston GP. Gene expression, dose-response, and phenotypic anchoring: Applications for toxicogenomics in risk assessment. Toxicological Sciences 2008; 105(2): 233-234.
Heinloth AN, Irwin RD, Boorman GA, Nettesheim P, Fannin RD, Sieber SO, et al. Gene expression profiling of rat livers reveals indicators of potential adverse effects. Toxicological Sciences 2004; 80: 193-202.
Zhang M, Chen M, Tong W. Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans. Chemical Research in Toxicology 2012; 25: 122-129.
Tachibana S, Shimomura A, Inadera H. Toxicity monitoring with primary cultured hepatocytes underestimates the acetaminophen-induced inflammatory responses of the mouse liver. Tohoku Journal of Experimental Medicine 2011; 225: 263-272.
Brunet S, Thibault P, Gagnon E, Kearney P, Bergeron JJ, Desjardins M. Organelle proteomics: Looking at less to see more. Trends in Cell Biology 2003; 13: 629-638. DOI: 10.1016/j.tcb.2003.10.006
Wetmore BA, Merrick BA. Toxicoproteomics: Proteomics applied to toxicology and pathology. Toxicologic Pathology 2004; 32: 619-642.
Tyers M, Mann M. From genomics to proteomics. Nature 2003; 422: 193-197.
Van Summeren A, Renes J, van Delft JHM, Kleinjans JCS, Mariman ECM. Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity. Toxicology in Vitro 2012; 26: 373-385. DOI: 10.1016/j.tiv.2012.01.012
Amacher DE. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicology and Applied Pharmacology 2010; 245: 134-142. DOI: 10.1016/j.taap.2010.02.011
Craig A, Sidaway J, Holmes E, Orton T, Jackson D, Rowlinson R, et al. Systems toxicology: Integrated genomic, proteomic and metabonomic analysis of methapyrilene induced hepatotoxicity in the rat. Journal of Proteome Research 2006; 5: 1586-1601.
Gouon-Evans V, Boussemart L, Gadue P, Nierhoff D, Koehler CI, Kubo A, et al. BMP-4 is required for hepatic specification of mouse embryonic stem cell–derived definitive endoderm. Nature Biotechnology 2006; 24: 1402-1411.
Hay DC, Zhao D, Ross A, Mandalam R, Lebkowski J, Cui W. Direct differentiation of human embryonic stem cells to hepatocyte-like cells exhibiting functional activities. Cloning Stem Cells 2007; 9: 51-62.
Söderdahl T, Küppers-Munther B, Heins N, Edsbagge J, Björquist P, Cotgreave I, et al. Glutathione transferases in hepatocyte-like cells derived from human embryonic stem cells. Toicology in Vitro 2007; 21: 929-937.
McNeish J. Embryonic stem cells in drug discovery. Nature Reviews Drug Discovery 2004; 3: 70-80.
McNeish JD. Stem cells as screening tools in drug discovery. Current Opinion in Pharmacology 2007; 7: 515-520.
Friedeich Ben-Nun I, Benvenisty N. Human embryonic stem cells as a cellular model for human disorders. Molecular and Cellular Endocrinology 2006; 252: 154-159.
Meng Q. Three-dimensional culture of hepatocytes for prediction of drug-induced hepatotoxicity. Expert Opinion on Drug Metabolism and Toxicology 2010; 6(6): 733-746.
Dunn JC, Tompkins RG, Yarmush ML. Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration.Biotechnology Progress 1991; 7: 237-245.
Tuschl G, Mueller SO. Effects of cell culture conditions on primary rat hepatocyte cell morphology and differential gene expression. Toxicology 2006; 218: 205-215.
Dash A, Inman W, Hoffmaster K, Sevidal S, Kelly J, Obach RS, et al. Liver tissue engineering in the evaluation of drug safety. Expert Opinion on Drug Metabolism and Toxicology 2009; 5(10): 1159-1174.
Mathijs K, Kienhuis AS, Brauers KJ, Jennen DG, Lahoz A, Kleinjans JC, et al. Assessing the metabolic competence of sandwich-cultured mouse primary hepatocytes. Drug Metabolism and Disposition 2009; 37: 1305-1311.
Liu X, Lecluyse EL, Brouwer KR, Lightfoot RM, Lee JI, Brouwer KLR. Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. Journal of Pharmacology and Experimental Therapeutics 1999; 289: 1592-1599.
Lee JK, Leslie EM, Zamek-Gliszczynski MJ, Brouwer KLR. Modulation of trabectedin (ET-743) hepatobiliary dispositionby miltudrug resistance-associated proteins (Mrps) may prevent hepatotoxicity. Toxicology and Applied Pharmacology 2008; 228(1): 17-23.
Xia L, Ng S, Han R, Tuo X, Xiao G, Leo HL, et al. Laminar-flow immediate-overlay hepatocyte sandwich perfusion system for drug hepatotoxicity testing. Biomaterials 2009; 30(30): 5927-5936.
Zhang S, Xia L, Kan CH, Xiao G, Ong SM, Toh YC, et al. Microfabricated silicon nitride membranes for hepatocyte sandwich culture. Biomaterials 2008; 29(29): 3993-4002.
Monga SPS, Hout MS, Baun MJ, Micsenyi A, Muller P, Tummalapalli L, et al. Mouse fetal liver cells in artificial capillary beds in three-dimensional four-compartment bioreactors. The American Journal of Pathology 2005; 167(5): 1279-1292.
Mandenius C-F, Andersson TB, Alves PM, Batzl-Hartmann C, Bjorquist P, Carrondo MJT, et al. Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitromodels derived from human embryonic stem cells and human cell lines - A report on the Vitrocellomics EU-project. Alternatives to Laboratory Animals 2011; 39: 147-171.
Luebke-Wheeler JL, Nedredal G, Yee L, Amiot BP, Nyberg SL. E-Cadherin protects primary hepatocyte spheroids from cell death by a caspase-independent mechanism. Cell Transplantation 2009; 18: 1281-1287.
Fey SJ, Wrzesinski K. Determination of drug toxicity using 3D spheroids constructed from an immortal human hepatocyte cell line. Toxicological Sciences 2012; 127(2): 403-411.
Walker TM, Rhodes PC, Westmoreland C. The differential cytotoxicity of methotrexate in rat hepatocyte monolayer and spheroid cultures. Toxicology in Vitro 2000; 14: 475-485.
LeCluyse EL, Witek RP, Andersen ME, Powers MJ. Organotypic liver culture models: Meeting current challenges in toxicity testing. Critical Reviews in Toxicology 2012; 42(6): 501-548.
Glicklis R, Merchuk JC, Cohen S. Modeling mass transfer in hepatocyte spheroids via cell viability, spheroid size and hepatocellular functions. Biotechnology and Bioengineering 2004; 86(6): 672-680.